Improving how we evaluate the toxicity of approved drugs

Affiliations

Review

Marcus M Reidenberg. Clin Pharmacol Ther. 2006 Jul.

. 2006 Jul;80(1):1-6.

doi: 10.1016/j.clpt.2006.03.006. Epub 2006 Jun 8.

¹ Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA. mmreid@med.cornell.edu

No abstract available

Similar articles

A proposal for radical changes in the drug-approval process.
Wood AJ. Wood AJ. N Engl J Med. 2006 Aug 10;355(6):618-23. doi: 10.1056/NEJMsb055203. N Engl J Med. 2006. PMID: 16899784 No abstract available.
Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP, Salas M, Delzell E. Glasser SP, et al. J Clin Pharmacol. 2007 Sep;47(9):1074-86. doi: 10.1177/0091270007304776. J Clin Pharmacol. 2007. PMID: 17766697
Clinical trials and public trust.
Kennedy D. Kennedy D. Science. 2004 Dec 3;306(5702):1649. doi: 10.1126/science.1107657. Science. 2004. PMID: 15576574 No abstract available.
The safety of niacin in the US Food and Drug Administration adverse event reporting database.
Alsheikh-Ali AA, Karas RH. Alsheikh-Ali AA, et al. Am J Cardiol. 2008 Apr 17;101(8A):9B-13B. doi: 10.1016/j.amjcard.2008.02.027. Am J Cardiol. 2008. PMID: 18375244 Review.
Criteria supporting the study of drugs in the newborn.
Ward RM, Benitz WE, Benjamin DK Jr, Blackmon L, Giacoia GP, Hudak M, Lasky T, Rodriguez W, Selen A. Ward RM, et al. Clin Ther. 2006 Sep;28(9):1385-98. doi: 10.1016/j.clinthera.2006.09.007. Clin Ther. 2006. PMID: 17062311 Review.

Gap in publication of comparative information on new medicines.
van Luijn JC, Stolk P, Gribnau FW, Leufkens HG. van Luijn JC, et al. Br J Clin Pharmacol. 2008 May;65(5):716-22. doi: 10.1111/j.1365-2125.2007.03092.x. Epub 2008 Feb 21. Br J Clin Pharmacol. 2008. PMID: 18294324 Free PMC article. Review.